Sight Sciences (SGHT) just posted its FY 2025 third quarter numbers with revenue of US$19.9 million and a basic EPS loss of US$0.16, while trailing 12 month revenue sits at US$76.1 million against a loss of US$0.89 per share. The company has seen quarterly revenue fluctuate between US$17.5 million and US$21.4 million over the past six quarters, with basic EPS losses ranging from US$0.16 to US$0.28. This keeps the focus firmly on how quickly margins might tighten up from here.

See our full analysis for Sight Sciences.

With the headline figures on the table, the next step is to set these results against the widely held narratives around growth, profitability and risk to see which stories still hold up and which ones the latest numbers quietly challenge.

Losses Narrow From US$14.2m To US$8.2m This Year

• Net loss for Q3 FY 2025 was US$8.2 million compared with US$14.2 million in Q1 FY 2025, while the trailing 12 month loss sits at US$46.1 million against US$76.1 million of revenue.
• What stands out for the bullish view is that analysts point to around 12% forecast revenue growth and about 1.8% yearly improvement in earnings over five years. However, the earnings profile is still a loss of US$46.1 million over the last 12 months, which keeps the gap to potential industry level margins wide.
• Supporters of the bullish case highlight the revenue growth outlook and the longer term narrowing of losses, but the latest trailing loss of US$46.1 million shows that any move toward the US Medical Equipment industry margin of about 12% is still theoretical at this stage.
• Analysts looking for future upside on revenue have to balance that against the fact that basic EPS for the last 12 months is a loss of US$0.89 per share, consistent with forecasts that do not show profitability within the next three years.

Bulls argue that revenue traction could eventually make this earnings profile look very different, but the current numbers give you a clear sense of how far the company still has to travel. 🐂 Sight Sciences Bull Case

Q3 EPS Loss Of US$0.16 Versus US$0.28 Earlier This Year

• Basic EPS loss moved from US$0.28 in Q1 FY 2025 to US$0.23 in Q2 and US$0.16 in Q3, while quarterly net losses over that stretch went from US$14.2 million to US$11.9 million and then to US$8.2 million on revenue that stayed in a fairly tight band between US$17.5 million and US$19.9 million.
• Skeptics focus on the bearish narrative that even with this pattern, the company is still unprofitable and is expected to remain so for at least three years, which lines up with trailing 12 month EPS of a US$0.89 loss and a trailing loss of US$46.1 million despite revenue around US$76.1 million.
• Bears argue that the combination of continued losses and forecasts for ongoing unprofitability reinforces concerns about funding needs and potential dilution, particularly when the business has not yet converted steady revenue in the US$17 million to US$21 million quarterly range into positive earnings.
• The recent narrowing of quarterly losses challenges the most pessimistic angle of that view, but the fact that losses are still substantial on all time frames backs the core bearish claim that profitability is not yet visible in the reported figures.

Bears warn that unless the earnings profile improves more decisively, the recent EPS trend may not be enough to change the bigger picture. 🐻 Sight Sciences Bear Case

P/S Of 2.8x Sits Below 9.5x Peer Average

• The company trades on a P/S of about 2.8x compared with roughly 2.9x for the broader US Medical Equipment industry and around 9.5x for peers, at the same time as it posts a trailing 12 month loss of US$46.1 million on US$76.1 million of revenue.
• Consensus narrative points to this lower P/S multiple and forecast revenue growth of about 11.9% a year as potential support for the stock, yet also flags ongoing unprofitability and recent insider selling as key risks that sit alongside that apparently cheaper sales multiple.
• On one hand, the valuation gap to peers at 9.5x P/S suggests the market is not paying the same premium for SGHT despite similar or better revenue growth expectations than the wider US market at 10.2% a year.
• On the other hand, the combination of a US$46.1 million trailing loss, negative EPS of US$0.89 over the last year and meaningful insider selling in the past three months is a clear reminder that a lower P/S can also reflect concern about the earnings profile rather than a simple pricing discount.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Sight Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this combination of gains and gaps leaves you undecided, take a closer look at the full picture and weigh it up for yourself, starting with 3 key rewards and 2 important warning signs.

See What Else Is Out There

With a trailing 12 month loss of US$46.1 million, negative EPS and no forecast path to profitability in the near term, earnings risk remains high.

If you want ideas where financial resilience takes center stage instead, run your eye over our 74 resilient stocks with low risk scores and compare how those businesses handle risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.